Latest Breaking News On - Amgen medinfo - Page 1 : comparemela.com

AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022

Very low LDL-C Levels Data Reinforces Long-Term Efficacy and Consistent Safety Profile of Repatha Observed in FOURIER-OLE THOUSAND OAKS, Calif., N.

AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022

NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS

/PRNewswire/ Amgen (NASDAQ:AMGN) today presented new compelling data from the Phase 3 FOURIER open label extension (OLE) studies of Repatha® (evolocumab) in.

NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS - Press Release

Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death80% of Patients Achieved Guideline Directed LDL-C L

AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)

/PRNewswire/ Amgen (NASDAQ:AMGN) today announced top-line results from two Repatha® (evolocumab) open label extension (OLE) studies to the Phase 3 FOURIER.